On this webpage, where nouns, verbs and adjectives are used in the singular, they will also apply to the plural e.g. fee will also cover fees, and review will also cover reviews.
This guidance and the associated review fees are in use from the date of the commencement of formal roll out of the applicable Technical Assurance -
- Pharmacy Assurance: 15 October 2018.
- Radiation Assurance: 16 April 2018.
It is to be used where Radiation and/or Pharmacy Assurance is being applied for and England, Northern Ireland or Wales is the lead nation. If Scotland is the lead nation for Pharmacy and/or Radiation Assurance, guidance should be sought from the NHS Research Scotland Permissions Co-ordinating Centre as to payment requirements.
Feedback can be given via our online survey.
- Payment flowchart
1.1. The purpose of this web page is to give guidance for funders, sponsors, HRA registered reviewers and their employers (where applicable) as to how payment for HRA Radiation and Pharmacy Technical Assurance reviews should be made. It also includes advice on budgeting for review costs and payment for amendments.
1.2 Prior to the implementation of Technical Assurance, there has been no national payment framework for the completion of technical reviews within the NHS for research purposes. Each trust/health board or private contractor set its own payment structures and these differed significantly between organisations. For Radiation, the review fee could range from no charge at all, to upwards of £700 per review. In terms of Pharmacy, reviews had not been charged for specifically, but had been included as part of a fixed site set-up fee. Similarly, review fees for amendments for Radiation vary significantly across trusts/health boards, again, ranging from no charge at all, through to hourly rates and fixed rate fees.
1.3 Following the evaluation of the Technical Assurances pilots, it was agreed that a standardised review fee should be introduced for both Pharmacy and Radiation Assurance, and that £500 per reviewer, per review, for new studies was an appropriate fee to reflect the workload required of a reviewer. The introduction of a standardised fee also enables sponsors and funders to consider the correct payment in the grant. This agreement was reached during discussions between the HRA’s Collaboration and Development Forum and major funders, and feedback from the Radiation and Pharmacy Guardian groups.
1.4 The decision was also taken to standardise the review fee for amendments submitted to Radiation Assurance and that £250 per reviewer, per review of each amendment was an appropriate fee, except in the situations described further in amendments.
1.5 Both the review and amendment fees have been classified as a Part A research cost and are exclusive of VAT.
1.6 The HRA cannot specify which trust/health board budget the review fee is paid into; this is an internal matter for the trust/health board, though the HRA does recommend that the reviewer’s employing department is reimbursed accordingly.
1.7 The review fee payments made to trusts/health boards are additional to any site set-up fees charged by participating sites.
1.8 All payments to trusts/health boards or private individuals for completion of the technical reviews include funding for the completion of quality assurance checks. No separate or additional payment is required by sponsors or applicants to cover this activity.
1.9 The review fee and amendment fee are subject to periodic review due to changes in inflation rates.
1.10 The HRA will indemnify the completion of HRA-managed reviews, but not the payment aspect of the process. Indemnification of self-managed reviews should be provided by the reviewing trust/health board and/or reviewer (depending on local arrangements). The HRA will not indemnify any aspect of self-managed reviews.
1.11 An overview of the entire payments process can be found in the Appendix.
2. Definitions and Responsibilities
The individual (or organisation)
who submits the application to either Pharmacy or Radiation Assurance and
corresponds with the Health Research Authority about the submission. The
applicant may be the sponsor or a representative of the sponsor (e.g. contract
research organisation, chief investigator (CI), member of the research team or research and development (R&D) office).
An agreement between a sponsor and a trust/health board to confirm as a minimum the service to be provided by the trust/health board, the payment required, and how and when the payment will be made. It is up to the sponsor and trust/health board to agree the most appropriate form of agreement for completion of the review and payment.
The organisation which, upon its
approval, provides funding to the sponsor for a research study.
2.4 Health Research Authority (HRA)
The HRA manages the Radiation
Assurance review process and reviewers on behalf of the UK, and the Pharmacy
Assurance review process and reviewers throughout England and Wales.
The Pharmacy Assurance review process and reviewers in Northern Ireland and Scotland are managed by the respective nations.
2.5 HRA-Managed Study
A study which goes through Radiation or Pharmacy Assurance where the selection and management of reviewers is conducted by the HRA.
For simplicity, studies going through Pharmacy Assurance where the lead nation is Northern Ireland or Scotland and where the selection and management of reviewers is conducted by that nation are included in this definition for the purposes of this guidance.
2.6 HRA Registered Reviewer/Reviewer
A Clinical Radiation Expert (CRE), Medical Physics Expert (MPE), Pharmacist, Pharmacy Technician or Radiopharmaceutical Scientist who has been recruited and trained to the agreed UK-wide standards to conduct technical radiation or pharmacy reviews in their area of expertise. A list of HRA registered reviewer registration numbers and employing trusts/health boards is available on the applicable Assurance pages of the HRA website.
2.7 NHS Trust/Health Board
The employer of the HRA registered reviewers; in England this is an NHS trust and in Wales and Northern Ireland this is a health board. The trust/health board confirms to the Sponsor how payment should be made and receives the payment for the completion of their reviewers’ reviews. Where the applicant confirms that the study will be self-managed, the trust/health board should follow its local procedures to agree any fees necessary for the completion of the technical review.
It should be noted that some HRA MPE and CRE registered reviewers may be employed by private institutions, work as a sole trader or on behalf of their own business. Where this guidance refers to the NHS trust/health board or the employer it may be taken to mean NHS trusts/health boards, any private institutions which employ reviewers, the reviewer's own business or the reviewer themselves where they are a sole trader.
2.8 Pharmacy Assurance
The centralised review by a HRA registreed pharmacy reviewer(s) of the technical pharmacy aspects of a clinical trial of investigational medicinal product (CTIMP).
2.9 Radiation Assurance
The centralised review by a HRA registered CRE and MPE reviewer(s) of the radiation aspects of clinical trials, for inclusion in Part B Section 3 of the IRAS form. Radiation Assurance also includes a consistency review by the HRA, which involves confirming consistency of radiation research exposures within and between study documents.
2.10 Review Completion
The review process may include alterations as a result of queries from reviewers and/or clarifications provided by the sponsor.
A review will only be considered complete once the HRA has issued an email to the sponsor confirming either Pharmacy or Radiation Assurance is in place.
2.11 Self-managed Study
A study which goes through Radiation or Pharmacy Assurance where the selection and management of reviewers is conducted by the applicant. The self-managed review process is only available to the following:
- Studies with a non-commercial sponsor; and
- The sponsor (or co-sponsor, including those with joint research office arrangements in place) is the same as the reviewing trust/health board; and
- The reviewers conducting the review are registered to conduct Radiation or Pharmacy Assurance reviews and are employed by the reviewing trust/health board;
- For Pharmacy Assurance only, the reviewers should have had input into the development of the protocol and associated documents.
For Pharmacy Assurance only, single site studies do not have to come through the process unless there is the possibility that they may expand to additional sites in future. They will only be accepted through the self-managed route, not the HRA-managed route.
2.12 Service Level Agreement (SLA)
See 2.2 Agreement.
The organisation which is responsible for seeking and securing funding for the research study; this organisation is also responsible for paying the trust/health board for completion of the Pharmacy and Radiation Assurance review in line with the method agreed with the trust/health board for doing so. In some instances the trust/health board may also be the sponsor.
3. Seeking Funding
3.1 Funding for the review fee must be sourced from study budgets or from grant funding. It is the responsibility of the Sponsor to seek appropriate funding, including that required for any potential amendments to be submitted at a later date.
3.2 From 01 April 2020 the HRA expects that all grant applications will have the set Technical Assurance review fees included where applicable to the study type.
3.3 The review fee for all new studies being processed through Radiation or
Pharmacy Assurance as a HRA-managed study is £500 per review, per reviewer,
excluding VAT. Where applicable for the vendor, VAT should be added to the review fee at the current rate.
3.4 The review fee for most amendments being processed through Radiation
Assurance as a HRA-managed study is £250 per review, per reviewer, excluding
VAT. Where ionising radiation exposures are being added to the study for the
first time, the full review fee of £500 per review, per reviewer excluding VAT
applies. In both cases VAT should be added to the review fee at the current rate, where applicable.
3.5 Amendments will not be reviewed through Pharmacy Assurance and
therefore there is no associated review fee.
3.6 The standardised review fee has been classified as a Research Cost (Part A) as per AcoRD guidelines.
3.7 The review fee for Pharmacy Assurance may be included in the industry
costing template in the future, but the fee for Radiation Assurance will not be included in this template.
3.8 The standardised review fee is not payable for self-managed studies;
however, sponsors should note that payment may be expected as part of local practices.
3.9 The HRA recommends that sponsors seek funding based on the study being
processed as HRA-managed in case it is not possible for the study to be self-managed.
3.10 When securing funding, sponsors should be mindful of the number of reviewers which may be required for each study based on the specialisms involved as each reviewer needed will incur an additional review fee as described in 3.3-3.6.
3.11 Reviewers may be available who cover multiple specialisms but as
availability may not be known until the review commences, sponsors are advised
to seek funding for the maximum number of reviewers required.
3.12 The HRA will ensure that reviewers of appropriate specialisms are assigned to each study review, even if the applicant is choosing the reviewers who will conduct the review.
3.13 The specialisms utilised in Pharmacy Assurance are:
a) Adult oncology;
b) Paediatric oncology;
c) Adult non-oncology;
d) Paediatric non-oncology
f) Advanced therapy IMPs (ATIMPs)
3.14 The modalities utilised for Medical Physics Experts (MPEs) are:
b) Nuclear medicine
3.15 The clinical specialisms utilised for Clinical Radiation Experts (CREs) are:
d) Vascular specialities;
Additionally CREs may have particular expertise in one or more of the following modalities:
b) Nuclear medicine;
It should be noted that due to the range of clinical specialisms this list is not exhaustive but is based on the most common types of research submitted for ethical review. Care should therefore be taken in particular when estimating the number of CRE Reviewers required.
4. Self-Managed Studies
4.1 As defined in definitions and responsibilities, self-management of a study is currently only available as an option to those studies listed in 2.11.
4.2 As described in seeking funding, there is no set review fee for self-managed studies. Agreement should be reached between the sponsor and trust/health board for an appropriate fee to develop the study protocol etc. and conduct the technical review.
4.3 An agreement for the completion and payment of the review is
recommended between the sponsor and trust/health board where the trust/health
board is a co-sponsor. It is for the sponsor and the trust/health board to
agree what form this will take and
how it will be managed.
4.4 Where the sponsor and trust/health board are the same organisation
there may be no requirement for an agreement for the conduct or payment of the review. Payment may still be required
according to local practices.
Cancelling the review
4.5 In some instances the applicant may plan to use the self-management route but later find that this is not possible e.g. the registered reviewer they were going to use is unavailable due to long-term sickness and the applicant’s timelines will not be met. In these cases the applicant can:
a) Use the HRA-managed process if they decide it will be beneficial, though payment will then be managed in accordance with HRA-managed studies or;
b) Decide not to proceed through Technical Assurance at all. For Radiation Assurance, applicants should seek MPE and CRE reviews themselves. For Pharmacy Assurance, applicants should follow the alternative site approval process for participating nations. Payment for these reviews will be managed directly with sites according to their processes and this guidance should not be used further.
5. HRA-Managed Studies
5.1 Single-site studies will not be processed as HRA-managed studies for Pharmacy Assurance, though they will be for Radiation Assurance.
All other studies will be eligible
to be processed as HRA-managed studies where Technical Assurance is being
5.2 When the HRA is assigning reviewers (as described in the below sections) it will do so by using the fewest number of reviewers and employing trusts/health boards wherever possible. This is in order to reduce the administrative burden on trusts/health boards and sponsors in processing payments.
5.3 Specialisms required will always be taken into consideration when assigning reviewers.
5.4 Where the lead nation is Scotland, reviewers will be chosen from that
nation in the first instance. Equally, where the lead nation is England,
Northern Ireland or Wales, reviewers will be chosen from one of these nations
in the first instance to ensure that appropriate funding is available for them.
5.5 Where no reviewers are available to undertake the review from the
applicable nations as given in 5.4 the HRA will choose a registered reviewer from another nation in line with its
internal processes. Alternatively,
the sponsor will have the option to wait for registered reviewers to be
available from the nation(s) given in 5.4. Where there are
implications for payment, the HRA will liaise with the sponsor to seek advice
as to how it would like to manage the selection of reviewers. Please refer to 5.11 for
5.6 Reviewers do not have to be from participating sites.
5.7 Where the sponsor has previously worked with certain trusts/health
boards (e.g. to undertake an MPE review), they should check the registered reviewer list to identify
whether these trusts/health boards have a reviewer registered with the HRA and
specify to the HRA (upon submission) their choice of reviewing trust/health
board. The sponsor will be able to choose up to three reviewing trusts/health
boards and may also request particular reviewers at those sites, all of which
must be specified at the time of submission.
5.8 Where a specific reviewer or trust/health board is identified from the
list and requested by the sponsor, the HRA will allocate the study to that
reviewer or another reviewer at that site, where availability allows.
5.9 Where no reviewers are available to undertake the review at the
requested trusts/health boards, the HRA will choose a registered reviewer from
another site from its list in line with its internal procedures. Alternatively, the sponsor will have the option to wait
for registered reviewers to be available at the request trusts/health boards.
5.10 Where the study is being processed through the HRA-managed route and the reviewer is based in England, Northern Ireland or Wales, the standard review fee will be applicable. Where a reviewer has been assigned from Scotland the review fee which is specified by the reviewer will be applicable.
5.11 In instances where the lead nation is England, Northern Ireland or
Wales and the reviewer is based in Scotland, the fee for the review will be specified by the reviewer. In instances
where the lead nation is Scotland but the reviewer is based in England, Northern
Ireland or Wales, the standardised review fee will be applicable.
5.12 It is up to the sponsor and trust/health board to agree the most appropriate form of agreement for
completion of the review and payment. This
process will vary dependent on local policies and procedures.
5.13 The HRA will provide the reviewer with the contact details of the
applicant to make the arrangements for payment.
5.14 Payment should be made to the trust/health board after the applicant
has received confirmation of technical review completion from the HRA except
where a review is cancelled, in which case payment should be made in line with Cancellation of the Review.
5.15 The HRA recommends that payment should be made from the sponsor to the
trust/health board within 30 days of receipt of confirmation of technical review completion (or cancellation).
Radiation Assurance - Specific Payment Arrangements for Private Reviewers
5.16 In some instances, reviewers may wish to act as private individuals. This would be appropriate where the reviewer is retired, for example, and is no longer working on behalf of their local NHS/HSC organisation, or where reviewers conduct reviews outside of the time spent working for their employer. Where this is the case, sponsors and reviewers who act as private individuals should note the following:
a) Payment for completion of the review should still be made in line with the Payments Framework Guidance.
b) If reviewers who are employed spend time completing reviews outside of their normal working hours, it is up to them and their employer to agree whether payment for completion of the review may be made to the reviewer from the sponsor via the employer into the reviewer’s wages or whether it should be made directly to the reviewer.
c) It is the sponsor's responsibility to check with their finance departments the arrangements for making payments to sole traders and limited companies, to ensure that they are made within HMRC rules. The HRA is not responsible for checking the payment arrangements comply with HMRC rules.
d) There may be implications for reviewers’ tax and national insurance contributions. Guidance is available from HMRC.
6.1 The HRA will process amendments through Radiation Assurance as requested by the sponsor. Further guidance on what changes to the study would lead to a review through Radiation Assurance can be found on the IRAS website.
6.2 Amendments to ionising radiation exposures of studies which already have Radiation Assurance will be
processed in line with HRA processes and will incur a fee of £250 plus VAT per
review, per reviewer where the study is HRA-managed.
6.3 Where an amendment is to add ionising radiation exposures for the first
time and Radiation Assurance is being applied for, the full review fee of £500
plus VAT per review, per reviewer, will apply where the study is HRA- managed.
6.4 Where an amendment is being reviewed as self-managed, the sponsor and
the trust/health board should agree an appropriate fee for the completion of
6.6 Where amendments are submitted as a result of the outcome of a quality
assurance check, payment may not be required for the completion of the
amendment review. Further information is available in Quality Assurance.
6.7 In line with the Pharmacy Assurance amendments guidance the HRA will not review any amendments to the technical pharmacy review.
7. Cancellation of the Review
7.1 No payment will be required when:
a) the technical review is cancelled by the applicant before it is sent to the reviewer; or
b) the technical review is cancelled by the applicant after it is sent to the reviewer, but no work has commenced on the review.
7.2 In some cases, the technical review may be cancelled after it has been sent to a reviewer and work has begun on the review but it is not completed. Reasons for cancellation of the technical review under this case may include, but are not limited to:
a) the study is cancelled in the UK and technical review is therefore no longer required;
b) the sponsor is amending the study design and/or documents so substantially that the completion of the review with the submitted documents would not be useful.
7.3 Where 7.2 applies, it will be the responsibility of the trust/health board and the sponsor to agree an appropriate fee for works already undertaken. This may be a partial re-imbursement to the trust/health board, or the full payment, depending on how much work the reviewer has undertaken prior to the review being cancelled.
7.4 The HRA is unable to mediate payment discussions regarding what would
be considered an appropriate fee for a partially-completed review, as it will
not have received information other than queries about the review and is not
able to assess the level of input each reviewer has given into the review.
7.5 If 7.2b applies and the applicant is
ready at a later date to re-submit the study for review, a new application
should be made. Where the study will be HRA-managed, the appropriate review fee
will be payable to reviewers conducting the review in line with HRA-Managed Studies and Amendments.
8. Quality Assurance
8.1 The HRA is committed to ensuring quality within the completed technical reviews and has implemented a quality assurance programme to assure stakeholders of our commitment. Quality is monitored based on feedback from sites, applicants, Research Ethics Committees (RECs), and the Administration of Radioactive Substances Advisory Committee (ARSAC). Further information on how the HRA manages quality assurance for the Technical Assurance programme is available on the Pharmacy or Radiation Assurance pages of the website.
8.2 Payment for quality assurance checks to be conducted by reviewers is
incorporated into the review fees and no separate payment is required for this activity.
8.3 In some instances feedback from stakeholders may raise issues with the
quality of the information provided within the review. In most of these cases
they can be resolved without the content of the review changing and therefore
there will be no impact on the payment already
8.4 Where further investigation or assurance is required because the issue
cannot be resolved between the applicant and the reviewer, a quality assurance
check may be conducted. Payment for quality assurance checks to be conducted by
reviewers is incorporated into the review fees and no separate payment is
required for this activity.
8.5 In very rare instances as a result of issues being raised by stakeholders or quality assurance checks being conducted, the content of the Radiation Assurance review may need to be amended. In this case the following will apply:
a) The original reviewer will amend the review in line with the findings of the quality assurance check; no additional payment will be required.
b) If the original reviewer is not available (e.g. they are on long-term sick leave) the HRA will attempt to assign the review to another reviewer with the requisite specialism within the same trust/health board; no additional payment will be required.
c) If the applicant requests to use another reviewer, or if point b is not possible, payment will be required to the employing trust/health board of the new reviewer in line with the details in Amendments.